Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


New two-year data for Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two causes of vision loss – Genentech/Roche

Written by | 9 Apr 2022

Genentech, announced that new two-year data from its Phase III studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.